XML 26 R17.htm IDEA: XBRL DOCUMENT v3.21.1

Common Stock, and Warrants With-Down Round Protection

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Common Stock, and Warrants With-Down Round Protection

NOTE 10 – COMMON STOCK, AND WARRANTS WITH-DOWN ROUND PROTECTION

	A.	1.	Description of the rights attached to the Common Stock
			Each share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of the Company’s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively.

	A.	2.	Description of the Series D units
			Holders of the Series D Units of the Company (each a “Unit” and, collectively, the “Units”), each consisted of (a) one share (collectively, the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (b) a five year warrant to purchase, at an exercise price of $4.50 per share, one share of Common Stock (collectively, the “Series D-1 Warrants”), (c) a five year warrant to purchase, at an exercise price of $5.75 per share, one share of Common Stock (collectively, the “Series D-2 Warrants”), and (d) a five year warrant to purchase, at an exercise price of $7.75 per share, one share of Common Stock (collectively, the “Series D-3 Warrants”, and together with the Series D-1 Warrants and Series D-2 Warrants, the “Warrants”).
			Placement Agent Compensation
			Pursuant to a placement agent agreement (the “Placement Agent Agreement”) with the placement agent for the Offering (the “Placement Agent”), at the closing of the sale of the Units the Company paid the Placement Agent, as a commission, a cash amount equal to 7% of the aggregate sales price of the Units, plus 3% of the aggregate sales price as a management fee plus a non-accountable expense allowance equal to 3% of the aggregate sales price of the Units. In addition, pursuant to the placement agent agreement, the company is required to issue to the Placement Agent warrants to purchase up to such number of shares of Common Stock equal to 10% of the aggregate Shares sold in the Offering plus warrants equal to 10% of the total number of the Warrants issued to the Purchasers in the Offering (collectively, the “Placement Agent Warrants”). The terms of the Placement Agent Warrants will be substantially similar to the Warrants except that the Placement Agent Warrants will also be exercisable on a cashless basis and will include full ratchet anti-dilution protection.

	B.	Stock-based compensation
		1.	Grants to non-employees

	a.	In connection with the 2017 Offering, the Company has issued to the Placement Agent (a) 5-year warrants to purchase up to 13,815,322 shares of Common Stock at an exercise price of $0.258 per share, (b) 5-year warrants to purchase up to 108,305 shares of Common Stock at an exercise price of $1.80 per share.(c) 5-year warrants to purchase up to 108,305 shares of Common Stock at an exercise price of $3.60 per share, and (d) 5-year warrants to purchase up to 108,305 shares of Common Stock at an exercise price of $5.40 per share. The terms of the Placement Agent warrants are substantially similar to the terms of the Series D Warrants except that the Placement Agent warrants may also be exercisable on a cashless basis at all times.
		In connection with February 2020 Offering, the Company has issued to the Placement Agent 5-year warrants to purchase up to 3,750,000 shares of Common Stock at an exercise price of $0.4 per share. During the year ending December 31, 2020 and 2019, $756 and $249 thousand, respectively, representing the fair value of warrants issued as consideration for placement agent services to AGI. This amount was accounted for as Warrants with down-round protection. Upon issuance, the fair value was recognized as an increase in additional paid in capital
		As of December 31, 2020, and 2019, the key inputs used in the fair value calculations of the warrant that were affected by the down-round protection were as follows:

Fair value calculations – Warrant		31-Dec-20				31-Dec-19
Dividend yield (%)			-				-
Expected volatility (%)			56.32				56.32
Risk free interest rate (%)			2.5				2.5
Expected term of options (years)			5				5
Exercise price (US dollars)			0.4				0.258-5.400
Share price (US dollars)			0.4				0.258
Fair value (US dollars)			0.2				0.003-0.134

		2.	Grants to employees
			In August 2007, Integrity Israel’s Board of Directors (“Integrity Israel’s Board”) approved a stock option plan (“Integrity Israel’s plan”) for the grant, without consideration of options exercisable into ordinary shares of NIS 0.01 par value of Integrity Israel to employees, officers and directors of Integrity Israel. The exercise price and vesting period for each grantee of options was determined by Integrity Israel’s Board and specified in such grantee’s option agreement. The options vested over a period of 1-12 quarters based on each grantee’s option agreements. Any option not exercised within 10 years after the date of grant thereof will expire.

In July 2010, following the merger with Integrity Israel, the Company adopted the 2010 Share Incentive Plan (the “2010 Share Incentive Plan”), pursuant to which the Company’s Board of Directors is authorized to grant options exercisable into Common Stock of the Company.

The purpose of the 2010 Share Incentive Plan is to offer an incentive to employees, directors, officers, consultants, advisors, suppliers and any other person or entity whose services are considered valuable to the Company, as well as to replace the Integrity Israel Plan and to replace all options granted in the past by Integrity Israel.

On January 1, 2019, the company issued a ten-year non-qualified stock option to our former President, for the purchase of 75 thousand shares of Common Stock at an exercise price of $4.50 per share, with three-year quarterly vesting commencing on the first quarter after the effective date.

Effective June, 2020, Erez Ben-Zvi has joined the Company as its Vice President of Product, Mr. Ben-Zvi will lead all sales and marketing activities for Integrity and will serve on the Company’s executive leadership team.

The Company granted Mr. Ben-Zvi annual award of NIS 210 thousand worth (approximately $ 61 thousand) of restricted stock units (the “RSU”) effective as of the employee Start Date and on each one-year anniversary following the employee Start Date subject to the approval of the board of directors (the “additional RSU”). The RSU and each of the Additional RSU (if approved by the board of directors), as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$ 0.40 per share). 1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed by the Company at the applicable date of vesting. The vesting schedule shall be also applied to each of the Additional RSUs granted, mutatis mutandis, such that the vesting period of each of the respective Additional RSU shall commence from its actual date of grant

Effective November, 2020, Mr. Shalom Shushan has joined the Company as its Chief Technology Officer, Mr. Shushan will lead all technology and research and development activities for Integrity and will serve on the Company’s executive leadership team.

The Company granted Mr. Shushan annual award of NIS 90 thousand worth (approximately $27 thousand) of restricted stock units (the “RSU”) effective as of the employee Start Date. Furthermore, on each one-year anniversary following the employee Start Date subject to the approval of the board of directors, Company shall grant the Employee with NIS 60 thousand worth of restricted stock units (the “Additional RSU’’). Both the RSU and each of the Additional RSU (if approved by the board of directors), as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$ 0.40 per share). 1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed by the Company at the applicable date of vesting. The vesting schedule shall be also applied to each of the Additional RSUs granted to the Employee, mutatis mutandis, such that the vesting period of each of the respective Additional RSU shall commence from its actual date of grant

Grants to Employees		Number				Weighted average exercise price (US$)
Balance outstanding of December 31,2018			3,992,610				4.7
Balance exercisable of December 31,2018			2,721,587			$	4.63
Granted during 2019			75,000			$	4.5
Forfeited during 2019			(2,039,525	)		$	4.51
Balance outstanding as of December 31,2019			2,028,085			$	4.88
Balance exercisable of December 31,2019			1,724,194			$	4.63
Granted during 2020			-			$	-
Forfeited during 2020			(335,014	)		$	4.51
Balance outstanding as of December 31,2020			1,693,071			$	4.95
Balance exercisable of December 31,2020			1,667,853				4.96

The following tables summarize information about options outstanding at December 31, 2020:

Exercise price (US$)				Outstanding at December 31, 2020				Exercisable at December 31, 2020				Weighted average remaining contractual life (years)
	4.50				1,298,859				1,273,651				6.54
	6.25				344,212				344,212				1.19
	7.75				50,000				50,000				6.26
					1,693,071				1,667,863

The fair value of options granted to employees during the years ended on December 31, 2019 was estimated at the dates of grant using the Black-Scholes option model. The following are the data and assumptions used:

Fair value calculations - Warrant		December 31, 2019
Dividend yield (%)			-
Expected volatility (%) (*)			56.32
Risk free interest rate (%)			2.5
Expected term of options (years)			5
Exercise price (US dollars)			0.258-5.400
Share price (US dollars) (**)			0.258
Fair value (US dollars)			0.004-0.134

		(*)	Due to the low trading volume of the Company’s Common Stock, the expected volatility for 2019 grants was based on a sample of 248 companies operating in the Healthcare Products industry, respectively.
		(**)	The Common Stock price, per share for the year ended December 31, 2019 reflects the Company’s management’s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2019, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series D Units.

X

- References

No definition available.

+ Details

Name:	us-gaap_EquityAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

+ Details

Name:	us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration